Braidwell LP Has $10.55 Million Stake in Vor Biopharma Inc. $VOR

Key Points

• Braidwell LP increased its Vor Biopharma stake by 22.8% in the second quarter, owning 573,104 shares valued at approximately $10.55 million. Institutional investors collectively own 97.29% of the company.
• Analysts maintain a generally positive outlook, with Vor Biopharma carrying a consensus “Moderate Buy” rating and an average price target of $43.38, despite some firms holding neutral or sell-equivalent views.
• Vor Biopharma shares opened at $24.76, versus a 52-week range of $6.50 to $49.95. The company reported a quarterly loss of $0.80 per share, missing estimates of a $0.69 loss, while analysts expect a full-year loss of $2.56 per share.

Braidwell LP increased its position in shares of Vor Biopharma Inc. (NASDAQ:VOR - Free Report) by 22.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 573,104 shares of the company's stock after acquiring an additional 106,330 shares during the period. Braidwell LP owned about 0.97% of Vor Biopharma worth $10,551,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Vor Biopharma in the first quarter valued at approximately $140,000. XTX Topco Ltd bought a new position in Vor Biopharma in the 2nd quarter valued at approximately $66,000. BNP Paribas Financial Markets boosted its position in Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock worth $296,000 after buying an additional 5,058 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Vor Biopharma during the 3rd quarter worth approximately $230,000. 97.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on VOR. Weiss Ratings raised shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a report on Tuesday, August 11th. Wedbush raised their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.38.

Vor Biopharma Price Performance

Shares of VOR opened at $24.76 on Thursday. Vor Biopharma Inc. has a 52-week low of $6.50 and a 52-week high of $49.95. The business's 50 day moving average price is $20.92 and its two-hundred day moving average price is $16.93.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, research analysts forecast that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source